コレステロール検査市場 - 世界の産業規模、シェア、動向、機会、予測：製品タイプ別、検査の種類別、処方形態別、エンドユーザー別、地域別、競合別、2020年～2030年

コレステロール検査の世界市場規模は2024年に123億6,000万米ドルとなり、2030年までのCAGRは6.92%で、予測期間中に堅調な成長が予測されています。

コレステロール検査は、脂質プロファイルまたは脂質パネルとも呼ばれ、血中の様々な脂質（主にコレステロールとトリグリセリド）のレベルを評価するために使用される重要な検査です。この検査では通常、総コレステロール、低比重リポ蛋白（LDLまたは「悪玉」コレステロール）、高比重リポ蛋白（HDLまたは「善玉」コレステロール）、トリグリセリドを測定します。これらの値は、心臓血管の健康状態を知る上で不可欠であり、冠動脈疾患、心臓発作、脳卒中などの潜在的なリスクを特定するのに役立ちます。LDL値が高く、HDL値が低いと、動脈にプラークが蓄積し、血流が制限され、深刻な心臓合併症を引き起こすリスクが高まります。定期的なコレステロール検査は、心臓病の家族歴のある人、糖尿病のある人、座りがちな生活で食生活が乱れている人には特に重要です。コレステロール値の異常を早期に発見することで、より健康的な食生活、運動量の増加、コレステロール低下薬の使用など、生活習慣の改善や医学的介入を適時に行うことができます。コレステロール値は年齢、遺伝、食事、健康状態など様々な要因に影響されるため、医療専門家に相談することが重要です。医療専門家は結果を正確に解釈し、コレステロールを管理し、長期的な心血管の健康を維持するための個別の戦略を推奨することができます。

市場促進要因

心血管疾患の有病率の上昇

主な市場課題

技術的限界

主要市場動向

個別化医療

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のコレステロール検査市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品タイプ別（テストキット、テストストリップ、その他）
  • 検査の種類別（総コレステロール検査、高密度リポタンパク質（HDL）コレステロール、低密度リポタンパク質（LDL）コレステロール、トリグリセリド/VLDLコレステロール検査）
  • 処方形態別（市販薬、処方箋ベース）
  • エンドユーザー別（病院・診療所、診断研究所、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米のコレステロール検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のコレステロール検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域のコレステロール検査市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のコレステロール検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのコレステロール検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Abbott Laboratories Inc.
• Beckman Coulter Inc.
• Horiba Ltd.
• Nova Biomedical Corp.
• Roche Holding Ag（F.Hoffmann-La Roche Ltd.）
• Randox Laboratories Ltd.
• Siemens Healthineers Gmbh
• Sekisui Diagnostics LLC
• Sinocare Inc.
• Thermo Fisher Scientific Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Cholesterol Testing Market was valued at USD 12.36 Billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 6.92% through 2030. A cholesterol test, also known as a lipid profile or lipid panel, is a vital medical examination used to assess the levels of various lipids-primarily cholesterol and triglycerides-in the bloodstream. This test typically measures total cholesterol, low-density lipoprotein (LDL or "bad" cholesterol), high-density lipoprotein (HDL or "good" cholesterol), and triglycerides. These values offer essential insights into a person's cardiovascular health and help identify potential risks for conditions such as coronary artery disease, heart attacks, and strokes. Elevated LDL levels and low HDL levels can increase the risk of plaque buildup in arteries, leading to restricted blood flow and serious heart complications. Routine cholesterol testing is particularly important for individuals with a family history of heart disease, those with diabetes, or people leading sedentary lifestyles with poor dietary habits. Early detection of abnormal cholesterol levels allows for timely lifestyle changes or medical interventions, such as adopting a healthier diet, increasing physical activity, or using cholesterol-lowering medications. Since cholesterol levels can be influenced by various factors-including age, genetics, diet, and overall health-it is essential to consult with a healthcare professional. They can interpret the results accurately and recommend personalized strategies for managing cholesterol and maintaining long-term cardiovascular wellness.

Key Market Drivers

Rising Prevalence of Cardiovascular Diseases

Cardiovascular diseases, including heart attacks and strokes, often have subtle or asymptomatic early stages. For instance, according to a 2024 article, coronary artery disease (CAD) is a common yet serious heart condition that can lead to heart attacks. A recent study, published in the European Heart Journal, highlights that measuring apolipoprotein B particles and lipoprotein(a) levels may improve risk prediction for CAD. These lipoproteins carry "bad" cholesterol in the blood and play a critical role in plaque buildup in coronary arteries. The Centers for Disease Control and Prevention (CDC) states that CAD is caused by plaque accumulation in the arteries supplying blood to the heart, emphasizing the importance of early screening and preventive care. Cholesterol testing helps identify individuals with high cholesterol levels, who are at an increased risk of developing CVDs. Early detection allows for timely intervention and lifestyle changes that can help prevent or manage the progression of these diseases. Cholesterol testing provides valuable information for risk assessment and stratification. Individuals with elevated cholesterol levels are categorized as high-risk patients for CVDs. This categorization helps healthcare providers tailor treatment and management strategies, potentially preventing future cardiovascular events. For individuals diagnosed with CVDs or at risk of developing them, cholesterol testing is used to monitor the effectiveness of treatments such as medication, dietary changes, and exercise. Regular testing helps healthcare professionals adjust treatment plans as needed to achieve target cholesterol levels. The rising prevalence of cardiovascular diseases underscores the importance of cholesterol testing as a critical tool for prevention, early detection, and management. The increasing demand for cholesterol testing is a natural response to the need to address the growing burden of CVDs and their associated risk factors.

Key Market Challenges

Technological Limitations

While point-of-care testing devices and home testing kits have improved accessibility, their accuracy might not always match that of laboratory-based testing, potentially affecting diagnostic reliability. Point-of-care testing devices and home testing kits might yield results that can vary from one test to another or from laboratory-based measurements. This variability can lead to uncertainty in interpreting results and making clinical decisions. Home testing kits and point-of-care devices rely on individuals performing the test correctly. User errors, such as improper sample collection or incorrect device operation, can significantly impact the accuracy of results. Proper calibration and maintenance of testing devices are crucial for accuracy. Without regular calibration and quality control, point-of-care devices might drift from accurate results over time. Inaccurate results from point-of-care testing or home testing kits can impact clinical decision-making. Incorrect management strategies based on unreliable results might harm patient outcomes.

Key Market Trends

Personalized Medicine

The trend toward personalized medicine will likely extend to cardiovascular health. Cholesterol testing can provide essential data for tailoring interventions and treatment plans based on an individual's unique risk profile. The trend toward personalized medicine has the potential to greatly impact cardiovascular health, and cholesterol testing plays a vital role in this shift. Personalized medicine aims to provide individualized healthcare based on an individual's unique genetic makeup, lifestyle, and other factors. Cholesterol testing offers essential data that can help tailor interventions and treatment plans specifically for an individual's risk profile. Based on an individual's cholesterol levels, genetic factors, medical history, and other health metrics, healthcare providers can create personalized treatment plans. This might involve lifestyle modifications, medication choices, and specific targets for cholesterol levels. Personalized medicine involves continuous monitoring of an individual's health markers. Cholesterol testing serves as a valuable tool for tracking progress and ensuring that the chosen interventions are effective. Regular testing encourages patient adherence to treatment plans. For individuals who require cholesterol-lowering medications, personalized medicine can guide the choice of medications and dosages. Certain medications might be more effective or better tolerated based on an individual's genetic and metabolic factors.

Key Market Players

• Abbott Laboratories Inc.
• Beckman Coulter Inc.
• Horiba Ltd.
• Nova Biomedical
• Roche Holding Ag (F.Hoffmann-La Roche Ltd.)
• Randox Laboratories Ltd.
• Siemens Healthineers Gmbh
• Sekisui Diagnostics LLC
• Sinocare Inc.
• Thermo Fisher Scientific Inc.

Report Scope:

In this report, the Global Cholesterol Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cholesterol Testing Market, By Product Type:

• Test Kits
• Test Strips
• Other

Cholesterol Testing Market, By Test Type:

• Total Cholesterol Test
• High-Density Lipoprotein (HDL) Cholesterol
• Low-Density Lipoprotein (LDL) Cholesterol
• Triglycerides/VLDL Cholesterol Test

Cholesterol Testing Market, By Prescription Mode:

• Over the Counter
• Prescription Based

Cholesterol Testing Market, By End User:

• Hospitals & Clinics
• Diagnostic Laboratories
• Others

Cholesterol Testing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cholesterol Testing Market.

Available Customizations:

Global Cholesterol Testing market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cholesterol Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type Type (Test Kits, Test Strips, Others)
  • 5.2.2. By Test Type (Total Cholesterol Test, High-Density Lipoprotein (HDL) Cholesterol, Low-Density Lipoprotein (LDL) Cholesterol, Triglycerides/VLDL Cholesterol Test)
  • 5.2.3. By Prescription Mode (Over the Counter, Prescription Based)
  • 5.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Cholesterol Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Test Type
  • 6.2.3. By Prescription Mode
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cholesterol Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Test Type
      • 6.3.1.2.3. By Prescription Mode
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Cholesterol Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Test Type
      • 6.3.2.2.3. By Prescription Mode
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Cholesterol Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Test Type
      • 6.3.3.2.3. By Prescription Mode
      • 6.3.3.2.4. By End User

7. Europe Cholesterol Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Test Type
  • 7.2.3. By Prescription Mode
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cholesterol Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Test Type
      • 7.3.1.2.3. By Prescription Mode
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Cholesterol Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Test Type
      • 7.3.2.2.3. By Prescription Mode
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Cholesterol Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Test Type
      • 7.3.3.2.3. By Prescription Mode
      • 7.3.3.2.4. By End User
  • 7.3.4. France Cholesterol Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Test Type
      • 7.3.4.2.3. By Prescription Mode
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Cholesterol Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Test Type
      • 7.3.5.2.3. By Prescription Mode
      • 7.3.5.2.4. By End User

8. Asia-Pacific Cholesterol Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Test Type
  • 8.2.3. By Prescription Mode
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Cholesterol Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Test Type
      • 8.3.1.2.3. By Prescription Mode
      • 8.3.1.2.4. By End User
  • 8.3.2. India Cholesterol Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Test Type
      • 8.3.2.2.3. By Prescription Mode
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Cholesterol Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Test Type
      • 8.3.3.2.3. By Prescription Mode
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Cholesterol Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Test Type
      • 8.3.4.2.3. By Prescription Mode
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Cholesterol Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Test Type
      • 8.3.5.2.3. By Prescription Mode
      • 8.3.5.2.4. By End User

9. South America Cholesterol Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Test Type
  • 9.2.3. By Prescription Mode
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cholesterol Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Test Type
      • 9.3.1.2.3. By Prescription Mode
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Cholesterol Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Test Type
      • 9.3.2.2.3. By Prescription Mode
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Cholesterol Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Test Type
      • 9.3.3.2.3. By Prescription Mode
      • 9.3.3.2.4. By End User

10. Middle East and Africa Cholesterol Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Test Type
  • 10.2.3. By Prescription Mode
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cholesterol Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Test Type
      • 10.3.1.2.3. By Prescription Mode
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Cholesterol Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Test Type
      • 10.3.2.2.3. By Prescription Mode
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Cholesterol Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Test Type
      • 10.3.3.2.3. By Prescription Mode
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Abbott Laboratories Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Beckman Coulter Inc.
• 14.3. Horiba Ltd.
• 14.4. Nova Biomedical Corp.
• 14.5. Roche Holding Ag (F.Hoffmann-La Roche Ltd.)
• 14.6. Randox Laboratories Ltd.
• 14.7. Siemens Healthineers Gmbh
• 14.8. Sekisui Diagnostics LLC
• 14.9. Sinocare Inc.
• 14.10. Thermo Fisher Scientific Inc.

15. Strategic Recommendations

16. About Us & Disclaimer